Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Arena Pharmaceuticals Inc Raises FY 2012 Revenue Guidance


Thursday, 9 Aug 2012 04:05pm EDT 

Arena Pharmaceuticals Inc announced an update to its fiscal 2012 financial guidance. Arena increased its fiscal 2012 revenue guidance from $66-$72 million to $91-$97 million, which includes the $20.0 million milestone payment received from Eisai for the inclusion in the FDA-approved prescribing information of the BLOOM-DM data and, although the timing remains uncertain, $65.0 million for milestone payments that Arena will receive from Eisai following DEA scheduling designation and delivery of BELVIQ launch supply. 

Company Quote

5.37
0.31 +6.13%
11 Jul 2014